vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Howard Hughes Holdings Inc. (HHH). Click either name above to swap in a different company.
Howard Hughes Holdings Inc. is the larger business by last-quarter revenue ($235.9M vs $183.1M, roughly 1.3× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 3.4%, a 9.9% gap on every dollar of revenue. On growth, Howard Hughes Holdings Inc. posted the faster year-over-year revenue change (18.4% vs -1.8%). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs -13.8%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Howard Hughes Holdings Inc., formerly the Howard Hughes Corporation, is a real estate development and management company based in The Woodlands, Texas. It was formed in 2010 as a spin-off from General Growth Properties (GGP). Most of its holdings are focused on several master-planned communities. It took its name from the original Howard Hughes Corporation, which had developed the planned community of Summerlin, Nevada, and later became a subsidiary of GGP.
AMPH vs HHH — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $235.9M |
| Net Profit | $24.4M | $8.1M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | 121.6% |
| Net Margin | 13.3% | 3.4% |
| Revenue YoY | -1.8% | 18.4% |
| Net Profit YoY | -35.7% | -25.6% |
| EPS (diluted) | $0.51 | $0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $235.9M | ||
| Q4 25 | $183.1M | $624.4M | ||
| Q3 25 | $191.8M | $390.2M | ||
| Q2 25 | $174.4M | $260.9M | ||
| Q1 25 | $170.5M | $199.3M | ||
| Q4 24 | $186.5M | $935.0M | ||
| Q3 24 | $191.2M | $327.1M | ||
| Q2 24 | $182.4M | $317.4M |
| Q1 26 | — | $8.1M | ||
| Q4 25 | $24.4M | $6.0M | ||
| Q3 25 | $17.4M | $119.5M | ||
| Q2 25 | $31.0M | $-12.1M | ||
| Q1 25 | $25.3M | $10.5M | ||
| Q4 24 | $38.0M | $156.3M | ||
| Q3 24 | $40.4M | $72.8M | ||
| Q2 24 | $37.9M | $21.1M |
| Q1 26 | — | — | ||
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — |
| Q1 26 | — | 121.6% | ||
| Q4 25 | 19.4% | 4.2% | ||
| Q3 25 | 13.2% | 48.6% | ||
| Q2 25 | 24.2% | 26.0% | ||
| Q1 25 | 21.9% | 24.0% | ||
| Q4 24 | 24.2% | 33.5% | ||
| Q3 24 | 29.8% | 60.6% | ||
| Q2 24 | 30.3% | 20.4% |
| Q1 26 | — | 3.4% | ||
| Q4 25 | 13.3% | 1.0% | ||
| Q3 25 | 9.0% | 30.6% | ||
| Q2 25 | 17.8% | -4.7% | ||
| Q1 25 | 14.8% | 5.3% | ||
| Q4 24 | 20.4% | 16.7% | ||
| Q3 24 | 21.1% | 22.2% | ||
| Q2 24 | 20.8% | 6.6% |
| Q1 26 | — | $0.14 | ||
| Q4 25 | $0.51 | $0.20 | ||
| Q3 25 | $0.37 | $2.02 | ||
| Q2 25 | $0.64 | $-0.22 | ||
| Q1 25 | $0.51 | $0.21 | ||
| Q4 24 | $0.74 | $3.14 | ||
| Q3 24 | $0.78 | $1.46 | ||
| Q2 24 | $0.73 | $0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $1.8B |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $3.8B |
| Total Assets | $1.6B | $11.2B |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $1.8B | ||
| Q4 25 | $282.8M | $1.5B | ||
| Q3 25 | $276.2M | $1.5B | ||
| Q2 25 | $231.8M | $1.4B | ||
| Q1 25 | $236.9M | $493.7M | ||
| Q4 24 | $221.6M | $596.1M | ||
| Q3 24 | $250.5M | $400.7M | ||
| Q2 24 | $217.8M | $436.8M |
| Q1 26 | — | — | ||
| Q4 25 | $608.7M | $5.1B | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | $5.1B | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — |
| Q1 26 | — | $3.8B | ||
| Q4 25 | $788.8M | $3.8B | ||
| Q3 25 | $776.7M | $3.8B | ||
| Q2 25 | $757.5M | $3.6B | ||
| Q1 25 | $751.3M | $2.8B | ||
| Q4 24 | $732.3M | $2.8B | ||
| Q3 24 | $727.7M | $2.6B | ||
| Q2 24 | $713.3M | $3.0B |
| Q1 26 | — | $11.2B | ||
| Q4 25 | $1.6B | $10.6B | ||
| Q3 25 | $1.7B | $10.7B | ||
| Q2 25 | $1.6B | $10.3B | ||
| Q1 25 | $1.6B | $9.3B | ||
| Q4 24 | $1.6B | $9.2B | ||
| Q3 24 | $1.5B | $9.4B | ||
| Q2 24 | $1.5B | $9.9B |
| Q1 26 | — | — | ||
| Q4 25 | 0.77× | 1.35× | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | 1.85× | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | — |
| Free Cash FlowOCF − Capex | $24.6M | — |
| FCF MarginFCF / Revenue | 13.4% | — |
| Capex IntensityCapex / Revenue | 4.5% | — |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $32.9M | $360.3M | ||
| Q3 25 | $52.6M | $149.8M | ||
| Q2 25 | $35.6M | $177.3M | ||
| Q1 25 | $35.1M | $-224.9M | ||
| Q4 24 | $29.0M | $337.1M | ||
| Q3 24 | $60.0M | $248.3M | ||
| Q2 24 | $69.1M | $-17.5M |
| Q1 26 | — | — | ||
| Q4 25 | $24.6M | $348.6M | ||
| Q3 25 | $47.2M | $137.7M | ||
| Q2 25 | $25.0M | $169.7M | ||
| Q1 25 | $24.4M | $-238.4M | ||
| Q4 24 | $16.6M | $317.1M | ||
| Q3 24 | $46.2M | $238.7M | ||
| Q2 24 | $63.1M | $-25.1M |
| Q1 26 | — | — | ||
| Q4 25 | 13.4% | 55.8% | ||
| Q3 25 | 24.6% | 35.3% | ||
| Q2 25 | 14.3% | 65.1% | ||
| Q1 25 | 14.3% | -119.6% | ||
| Q4 24 | 8.9% | 33.9% | ||
| Q3 24 | 24.1% | 73.0% | ||
| Q2 24 | 34.6% | -7.9% |
| Q1 26 | — | — | ||
| Q4 25 | 4.5% | 1.9% | ||
| Q3 25 | 2.8% | 3.1% | ||
| Q2 25 | 6.1% | 2.9% | ||
| Q1 25 | 6.3% | 6.8% | ||
| Q4 24 | 6.7% | 2.1% | ||
| Q3 24 | 7.2% | 2.9% | ||
| Q2 24 | 3.3% | 2.4% |
| Q1 26 | — | — | ||
| Q4 25 | 1.35× | 60.04× | ||
| Q3 25 | 3.03× | 1.25× | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | -21.35× | ||
| Q4 24 | 0.76× | 2.16× | ||
| Q3 24 | 1.48× | 3.41× | ||
| Q2 24 | 1.82× | -0.83× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
HHH
| Rental revenue | $113.5M | 48% |
| Master Planned Communities land sales | $99.6M | 42% |
| Other revenues | $11.0M | 5% |
| Builder price participation | $8.7M | 4% |
| Condominium rights and unit sales | $3.1M | 1% |
